BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares saw unusually-strong trading volume on Friday . Approximately 2,225,900 shares changed hands during mid-day trading, an increase of 119% from the previous session’s volume of 1,016,521 shares.The stock last traded at $5.73 and had previously closed at $5.67.

Several equities research analysts have weighed in on BCRX shares. BidaskClub upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, May 4th. Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.50 target price for the company in a research note on Tuesday, May 1st. Finally, ValuEngine upgraded shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $8.36.

The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.38 and a current ratio of 1.38. The company has a market capitalization of $566.24 million, a P/E ratio of -7.35 and a beta of 2.73.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.10). BioCryst Pharmaceuticals had a negative return on equity of 114.36% and a negative net margin of 392.09%. The company had revenue of $3.98 million for the quarter, compared to analyst estimates of $10.20 million. research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.87 EPS for the current fiscal year.

In other news, CMO William P. Sheridan sold 42,112 shares of BioCryst Pharmaceuticals stock in a transaction on Friday, June 1st. The shares were sold at an average price of $6.30, for a total transaction of $265,305.60. Following the completion of the sale, the chief marketing officer now directly owns 63,170 shares in the company, valued at $397,971. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 5.21% of the company’s stock.

Large investors have recently bought and sold shares of the company. BlackRock Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 15.0% during the fourth quarter. BlackRock Inc. now owns 7,614,280 shares of the biotechnology company’s stock worth $37,386,000 after purchasing an additional 993,100 shares during the last quarter. Citadel Advisors LLC raised its holdings in shares of BioCryst Pharmaceuticals by 4,343.1% during the first quarter. Citadel Advisors LLC now owns 462,079 shares of the biotechnology company’s stock worth $2,204,000 after purchasing an additional 451,679 shares during the last quarter. Rock Springs Capital Management LP raised its holdings in shares of BioCryst Pharmaceuticals by 80.6% during the fourth quarter. Rock Springs Capital Management LP now owns 812,500 shares of the biotechnology company’s stock worth $3,989,000 after purchasing an additional 362,500 shares during the last quarter. Deutsche Bank AG raised its holdings in shares of BioCryst Pharmaceuticals by 106.1% during the fourth quarter. Deutsche Bank AG now owns 524,666 shares of the biotechnology company’s stock worth $2,573,000 after purchasing an additional 270,147 shares during the last quarter. Finally, Eversept Partners LLC purchased a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth $974,000. Institutional investors and hedge funds own 89.91% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.